<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03306225</url>
  </required_header>
  <id_info>
    <org_study_id>ENDOSTREPTO</org_study_id>
    <nct_id>NCT03306225</nct_id>
  </id_info>
  <brief_title>Characterization of Endocarditis to Streptococci and Impact of the CMI on the Future of the Patients</brief_title>
  <official_title>Characterization of Endocarditis to Streptococci and Impact of the CMI on the Future of the Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Paris Saint Joseph</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Paris Saint Joseph</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The infectious endocarditis is a grave infection the incidence of which is at present
      esteemed at 30-100 episodes by million inhabitants a year.

      This infection is marked with a heavy morbi-mortality.Preliminary studies seem to show an
      abnormally high death rate at the patients presenting an infectious endocarditis to
      streptococci with an inhibitive minimal concentration raised to the amoxicilline. The aim of
      the study is to describe the epidemiology and the clinical presentations of the patients
      presenting an endocarditis to streptococci
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of factors associated to the mortality in the patients presenting an endocarditis to streptococci.</measure>
    <time_frame>an average of one year</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Endocarditis, Bacterial</condition>
  <eligibility>
    <study_pop>
      <textblock>
        all patient diagnostised for endocarditis between 2010 and 2015
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  endocartitis with steptococci with Duke's criteria

        Exclusion Criteria:

          -  age &lt; 18 years

          -  suspiscious endocarditis without Duke's criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>PILMIS Benoit, MD</last_name>
    <phone>01 44 12 33 33</phone>
    <email>bpilmis@hpsj.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LE MONNIER Alban, Pr</last_name>
    <phone>0144123333</phone>
    <email>alemonnier@hpsj.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helene BEAUSSIER, PharmD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2017</study_first_submitted>
  <study_first_submitted_qc>October 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2017</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis</mesh_term>
    <mesh_term>Endocarditis, Bacterial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

